NEW YORK (GenomeWeb) – Signal Genetics reported after the close of the market Wednesday that its fourth quarter revenues were essentially flat year over year.

For the three months ended Dec. 31, 2015, the company reported revenues of $659,000 compared to $655,000 in Q4 2014. Signal attributed the rise in revenues to an increase in testing volume for its MyPRS myeloma risk test.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.